I think the Doubleline website does a good job of explaining how it works, but I wonder how many people did proper research on it.

“Historically, this has worked,” said Dr. Jeffrey Henderson, associate professor of medicine and molecular microbiology at Washington University School of Medicine in St. Louis. “Before we had vaccines, this was used for infectious diseases like measles and diphtheria.”
Convalescent plasma was also successfully used during the 1918 flu pandemic, he said.
Doctors say protocols, such as dosage, are still uncertain for COVID-19 patients, but they believe the method is worth trying, at least until an effective COVID-19 vaccine or treatment is developed.
The Mayo Clinic and other U.S. sites are conducting a clinical study. Similar trials are under way in other countries where the virus has hit and some data has begun to emerge.
In one trial in China, levels of the virus in five seriously ill COVID-19 patients were undetectable after plasma transfusions, according to study results published last week in The Journal of the American Medical Association.

Yesterday, the stock market fell 1.5%, supposedly due to an unfavorable employment report. My personal belief is the market is heavily influenced by high frequency algorithm trading in the short term. I also believe that upcoming data on the economy and COVID-19 will drive the market lower over the next few quarters. For now, I believe that it is best to be safe and wait for a better opportunity to rebalance into stocks.

The problem with the NAV being wrong for the mutual funds is that on days when the ETF’s market price trades at a discount to NAV, that means investors who bought the mutual fund essentially overpaid for its elevated NAV, while those selling received more for their sale than they should have. There is ultimately a delay, as the stale prices for the mutual fund’s bond portfolio have to adjust. Investors saw the consequences of that delay on March 13, when the Vanguard mutual fund fell 0.5% on a day when the ETF rallied 4.2%.
In an email to Barron’s, AlphaCentric stated, “We believe the NAV of the AlphaCentric Income Opportunities fund was accurately priced each day. The price reflects the fair value of its underlying portfolio of residential mortgaged backed securities, not equities.…The AlphaCentric fund’s daily pricing was done by ICE, which is one of the largest and most respected independent pricing services.” Yet ETF experts say that such fair-valuation services employ limited data. “Only about 20% of the bond universe trades every day,” says Reggie Browne, a principal at market maker GTS with a long history developing the ETF business. “How do you go about calculating fair value for something that doesn’t trade? The ETF is priced minute by minute, not a static NAV.”

D&C have good funds but many of them are riskier and it shows at market stress such as 2008 and many times when stocks go down and 2020 is no different
For YTD
Allocation DODBX -23.4...PRWCX -16.2...JABAX -13.1
Mostly US LC: DODGX -32.1....SPY -22.4
Foreign stocks: DODFX -34.5...AFCNX -21.9
BTW, all the funds above have better long term(1-3-5-10-15 years) risk/reward than D&C funds too.

“I think you need more transparency where bonds are trading real time, [to aggregate] where the prices are at and find a best bid, best offer [so that] there’s a lot of increased confidence where bonds are trading, just like you have in equities,”

Last February, there were $6T in bond funds (about $4.5T in OEFs) and I understand in March, like $250B in redemptions.

..... the lack of volatility providing (for some funds) false sense of security; therefore, more shocking the surprise when a crisis happens, which makes bond investors not used to drawdown, head for the door.

..... I see some bond funds like icebergs now.